Novo Nordisk A/S
NVONovo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
Drugs in Pipeline
108
Phase 3 Programs
78
Upcoming Catalysts
8
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
12 upcoming, 1 past
CagriSema (Cagrilintide B and Semaglutide I) Phase 2 Est. Readout
Primary completion for CagriSema (Cagrilintide B and Semaglutide I) trial (NCT06797869) in Diabetes Mellitus, Type 2
statistically significant reductions in blood sugar and body weight compared to placebo
SourceOral semaglutide Phase 3 Est. Readout
Primary completion for Oral semaglutide trial (NCT07271251) in Type 2 Diabetes
Met primary endpoint with statistically significant and clinically relevant HbA1c reductions versus placebo at doses of 2.4 mg and 1.0 mg each when added to basal insulin. Accompanied by robust bodyweight reduction with no additional hypoglycaemia risk.
Source10 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How NVO's past catalysts played out
NNC6019-0001
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Semaglutide 1.0 mg
Obesity
insulin degludec/insulin aspart
Diabetes
Semaglutide 1 mg
Diabetes Mellitus, Type 2
insulin lispro
Diabetes
Semaglutide J
Diabetes Mellitus, Type 2
turoctocog alfa pegol (N8-GP)
Haemophilia A
DCR-PHXC
Primary Hyperoxaluria Type 1 (PH1)
exenatide
Diabetes
repaglinide and metformin combination tablet
Diabetes
NNC0487-0111
Obesity
Insulin glargine U100
Diabetes Mellitus, Type 2
repaglinide
Diabetes
biphasic human insulin 50
Diabetes
insulin human
Diabetes
inhaled human insulin
Diabetes
Etavopivat
Sickle Cell Disease
semaglutide 50 mg
Overweight and Obesity
CagriSema (Cagrilintide B and Semaglutide I)
Obesity
Canagliflozin
Diabetes
sulfonylurea
Diabetes
vatreptacog alfa (activated)
Congenital Bleeding Disorder
biphasic insulin aspart 70
Diabetes
estradiol, 25 mcg
Menopause
17-beta estradiol
Genetic Disorder
estradiol, 10 mcg
Menopause
Semagludtide
Early Alzheimer's Disease
glibenclamide
Diabetes
eptacog alfa (activated)
Acquired Bleeding Disorder
Cagrisema
Obesity
Norditropin
Growth Hormone Disorder
biphasic human insulin 30
Diabetes
biphasic insulin aspart
Diabetes
Cagrilintide
Obesity or Overweight
Concizumab
Congenital Bleeding Disorder
biphasic human insulin
Diabetes
Insulin Icodec
Diabetes Mellitus, Type 2
human insulin
Diabetes
insulin NPH
Diabetes
turoctocog alfa pegol
Congenital Bleeding Disorder
rosiglitazone
Diabetes
biphasic insulin aspart 50
Diabetes
DPP-4 inhibitor
Diabetes
NNC0365-3769 (Mim8)
Haemophilia A
Insulin Glargine 100U/mL
Diabetes Mellitus, Type 2
Norditropin®
Growth Hormone Deficiency in Children
Ziltivekimab B
Cardiovascular Risk
NNC0365-3769 (Mim8) PPX
Haemophilia A
Faster aspart
Diabetes Mellitus, Type 1
Liraglutide 3.0 mg
Metabolism and Nutrition Disorder
basal insulin
Diabetes
Etavopivat A
Sickle Cell Disease
sulphonylurea
Diabetes
nonacog beta pegol
Congenital Bleeding Disorder
NPH insulin
Diabetes
Turoctocog alfa
Haemostasis
Insuline glargine U100 (reduced)
Diabetes Mellitus, Type 2
Ziltivekimab
Heart Failure
Oral semaglutide
Diabetes Mellitus, Type 2
0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)
Menopause
Faster-acting insulin aspart
Diabetes
Semaglutide 0.5 mg
Diabetes
somapacitan
Adult Growth Hormone Deficiency
human soluble insulin
Diabetes
oral anti-diabetic drug
Diabetes
Mim8
Haemophilia A
IcoSema
Type 2 Diabetes
insulin detemir
Diabetes
Semaglutide 2.4 mg
Obesity
somatropin
Growth Hormone Disorder
biphasic insulin aspart 30
Diabetes
activated recombinant human factor VII
Acquired Bleeding Disorder
Semaglutide
Obesity
insulin aspart
Diabetes
insulin degludec/liraglutide
Diabetes
insulin degludec
Diabetes
catridecacog
Congenital Bleeding Disorder
liraglutide
Diabetes
CDR132L
Heart Failure
orlistat
Metabolism and Nutrition Disorder
NNC109-0012
Inflammation
NNC0174-0833
Overweight
NNC0114-0006
Diabetes
Norditropin® FlexPro® pen
Growth Hormone Disorder
NNC0194-0499
Alcohol-related Liver Disease
Semaglutide (administered by PDS290 pen)
Healthy Volunteers Diabetes Mellitus, Type 2
COR-001
Anemia
insulin 338 (GIPET I)
Diabetes
recombinant interleukin-21
Cancer
NNC0662-0419
Overweight
NNC 0151-0000-0000
Inflammation
NNC0487-0111 subcutanous
Type 2 Diabetes (T2D)
NDec - oral decitabine-tetrahydrouridine
Sickle Cell Disease
NNC126-0083
Growth Hormone Disorder
EX1000
Diabetes
UBT251
Overweight
Dipeptidyl peptidase-4 inhibitors
Diabetes Mellitus, Type 2
NNC0519-0130
Diabetes Mellitus, Type 2
activated recombinant human factor VII, long acting
Congenital Bleeding Disorder
NNC0194 0499 50 mg/mL
Non-alcoholic Steatohepatitis
Semaglutide (administered by DV3396 pen)
Healthy Volunteers Diabetes Mellitus, Type 2
nedosiran
Primary Hyperoxaluria
NNC0480-0389
Diabetes Mellitus, Type 2
Cagrilintide 2.4 mg
Diabetes Mellitus, Type 2
Fast-acting insulin aspart
Diabetes Mellitus, Type 1
NNC0090-2746
Diabetes
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg
Obesity
NNC0385-0434 A 15 mg
Atherosclerotic Cardiovascular Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NNC6019-0001 | Phase 3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | - | - |
Semaglutide 1.0 mg | Phase 3 | Obesity | - | - |
insulin degludec/insulin aspart | Phase 3 | Diabetes | - | - |
Semaglutide 1 mg | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
insulin lispro | Phase 3 | Diabetes | - | - |
Semaglutide J | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
turoctocog alfa pegol (N8-GP) | Phase 3 | Haemophilia A | - | - |
DCR-PHXC | Phase 3 | Primary Hyperoxaluria Type 1 (PH1) | - | - |
exenatide | Phase 3 | Diabetes | - | - |
repaglinide and metformin combination tablet | Phase 3 | Diabetes | - | - |
NNC0487-0111 | Phase 3 | Obesity | - | - |
Insulin glargine U100 | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
repaglinide | Phase 3 | Diabetes | - | - |
biphasic human insulin 50 | Phase 3 | Diabetes | - | - |
insulin human | Phase 3 | Diabetes | - | - |
inhaled human insulin | Phase 3 | Diabetes | - | - |
Etavopivat | Phase 3 | Sickle Cell Disease | - | - |
semaglutide 50 mg | Phase 3 | Overweight and Obesity | - | - |
CagriSema (Cagrilintide B and Semaglutide I) | Phase 3 | Obesity | - | - |
Canagliflozin | Phase 3 | Diabetes | - | - |
sulfonylurea | Phase 3 | Diabetes | - | - |
vatreptacog alfa (activated) | Phase 3 | Congenital Bleeding Disorder | - | - |
biphasic insulin aspart 70 | Phase 3 | Diabetes | - | - |
estradiol, 25 mcg | Phase 3 | Menopause | - | - |
17-beta estradiol | Phase 3 | Genetic Disorder | - | - |
estradiol, 10 mcg | Phase 3 | Menopause | - | - |
Semagludtide | Phase 3 | Early Alzheimer's Disease | - | - |
glibenclamide | Phase 3 | Diabetes | - | - |
eptacog alfa (activated) | Phase 3 | Acquired Bleeding Disorder | - | - |
Cagrisema | Phase 3 | Obesity | - | - |
Norditropin | Phase 3 | Growth Hormone Disorder | - | - |
biphasic human insulin 30 | Phase 3 | Diabetes | - | - |
biphasic insulin aspart | Phase 3 | Diabetes | - | - |
Cagrilintide | Phase 3 | Obesity or Overweight | - | - |
Concizumab | Phase 3 | Congenital Bleeding Disorder | - | - |
biphasic human insulin | Phase 3 | Diabetes | - | - |
Insulin Icodec | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
human insulin | Phase 3 | Diabetes | - | - |
insulin NPH | Phase 3 | Diabetes | - | - |
turoctocog alfa pegol | Phase 3 | Congenital Bleeding Disorder | - | - |
rosiglitazone | Phase 3 | Diabetes | - | - |
biphasic insulin aspart 50 | Phase 3 | Diabetes | - | - |
DPP-4 inhibitor | Phase 3 | Diabetes | - | - |
NNC0365-3769 (Mim8) | Phase 3 | Haemophilia A | - | - |
Insulin Glargine 100U/mL | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Norditropin® | Phase 3 | Growth Hormone Deficiency in Children | - | - |
Ziltivekimab B | Phase 3 | Cardiovascular Risk | - | - |
NNC0365-3769 (Mim8) PPX | Phase 3 | Haemophilia A | - | - |
Faster aspart | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Liraglutide 3.0 mg | Phase 3 | Metabolism and Nutrition Disorder | - | - |
basal insulin | Phase 3 | Diabetes | - | - |
Etavopivat A | Phase 3 | Sickle Cell Disease | - | - |
sulphonylurea | Phase 3 | Diabetes | - | - |
nonacog beta pegol | Phase 3 | Congenital Bleeding Disorder | - | - |
NPH insulin | Phase 3 | Diabetes | - | - |
Turoctocog alfa | Phase 3 | Haemostasis | - | - |
Insuline glargine U100 (reduced) | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Ziltivekimab | Phase 3 | Heart Failure | - | - |
Oral semaglutide | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) | Phase 3 | Menopause | - | - |
Faster-acting insulin aspart | Phase 3 | Diabetes | - | - |
Semaglutide 0.5 mg | Phase 3 | Diabetes | - | - |
somapacitan | Phase 3 | Adult Growth Hormone Deficiency | - | - |
human soluble insulin | Phase 3 | Diabetes | - | - |
oral anti-diabetic drug | Phase 3 | Diabetes | - | - |
Mim8 | Phase 3 | Haemophilia A | - | - |
IcoSema | Phase 3 | Type 2 Diabetes | - | - |
insulin detemir | Phase 3 | Diabetes | - | - |
Semaglutide 2.4 mg | Phase 3 | Obesity | - | - |
somatropin | Phase 3 | Growth Hormone Disorder | - | - |
biphasic insulin aspart 30 | Phase 3 | Diabetes | - | - |
activated recombinant human factor VII | Phase 3 | Acquired Bleeding Disorder | - | - |
Semaglutide | Phase 3 | Obesity | - | - |
insulin aspart | Phase 3 | Diabetes | - | - |
insulin degludec/liraglutide | Phase 3 | Diabetes | - | - |
insulin degludec | Phase 3 | Diabetes | - | - |
catridecacog | Phase 3 | Congenital Bleeding Disorder | - | - |
liraglutide | Phase 3 | Diabetes | - | - |
CDR132L | Phase 2 | Heart Failure | - | - |
orlistat | Phase 2 | Metabolism and Nutrition Disorder | - | - |
NNC109-0012 | Phase 2 | Inflammation | - | - |
NNC0174-0833 | Phase 2 | Overweight | - | - |
NNC0114-0006 | Phase 2 | Diabetes | - | - |
Norditropin® FlexPro® pen | Phase 2 | Growth Hormone Disorder | - | - |
NNC0194-0499 | Phase 2 | Alcohol-related Liver Disease | - | - |
Semaglutide (administered by PDS290 pen) | Phase 2 | Healthy Volunteers Diabetes Mellitus, Type 2 | - | - |
COR-001 | Phase 2 | Anemia | - | - |
insulin 338 (GIPET I) | Phase 2 | Diabetes | - | - |
recombinant interleukin-21 | Phase 2 | Cancer | - | - |
NNC0662-0419 | Phase 2 | Overweight | - | - |
NNC 0151-0000-0000 | Phase 2 | Inflammation | - | - |
NNC0487-0111 subcutanous | Phase 2 | Type 2 Diabetes (T2D) | - | - |
NDec - oral decitabine-tetrahydrouridine | Phase 2 | Sickle Cell Disease | - | - |
NNC126-0083 | Phase 2 | Growth Hormone Disorder | - | - |
EX1000 | Phase 2 | Diabetes | - | - |
UBT251 | Phase 2 | Overweight | - | - |
Dipeptidyl peptidase-4 inhibitors | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
NNC0519-0130 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
activated recombinant human factor VII, long acting | Phase 2 | Congenital Bleeding Disorder | - | - |
NNC0194 0499 50 mg/mL | Phase 2 | Non-alcoholic Steatohepatitis | - | - |
Semaglutide (administered by DV3396 pen) | Phase 2 | Healthy Volunteers Diabetes Mellitus, Type 2 | - | - |
nedosiran | Phase 2 | Primary Hyperoxaluria | - | - |
NNC0480-0389 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Cagrilintide 2.4 mg | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Fast-acting insulin aspart | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
NNC0090-2746 | Phase 2 | Diabetes | - | - |
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg | Phase 2 | Obesity | - | - |
NNC0385-0434 A 15 mg | Phase 2 | Atherosclerotic Cardiovascular Disease | - | - |
diabetes
9 drugs in this indication
Diabetes Mellitus, Type 2
2 drugs in this indication
Congenital Bleeding Disorder
2 drugs in this indication
CKD
1 drug in this indication
Growth Hormone Deficiency in Children
1 drug in this indication
gastric issues
1 drug in this indication
MACE risk reduction
1 drug in this indication
hemophilia A
1 drug in this indication
Obesity or Overweight
1 drug in this indication
Heart Failure
1 drug in this indication
Inflammation
1 drug in this indication
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
1 drug in this indication
Obesity
1 drug in this indication
Overweight
1 drug in this indication
Haemophilia A
1 drug in this indication
Healthy Volunteers Diabetes Mellitus, Type 2
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Novo Nordisk A/S's drug pipeline?→
CatalystAlert tracks 108 drug candidates in Novo Nordisk A/S's (NVO) pipeline across Phase 3, Phase 2. Its lead program is NNC6019-0001 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Novo Nordisk A/S's next FDA catalyst?→
Novo Nordisk A/S's (NVO) next tracked catalyst is a Phase 2 expected December 14, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NVO biotech catalysts?→
Add NVO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Novo Nordisk A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.